Tag Archives: VIR

Hot Medical Stocks To Own For 2022

A new study published in the Journal of the American Medical Association found that marijuana legalization laws are not associated with increased use amongst high school students.

“Consistent with estimates from prior studies, there was little evidence that [recreational marijuana laws] or [medical marijuana laws] encourage youth marijuana use,” reads the paper.

The study builds upon a previous paper that used data from the Youth Risk Behavior Survey (YRBS) for the period 1993-2017, which found that marijuana adoption was associated with an 8% decrease in the odds of marijuana use among high school students. 

This earlier study used pre-legalization and post-legalization data from only 7 states and pre– and post–recreational sales data from only 3 states. The new study included data from up to 2019, encompassing 10 legal adult-use states.

With these additional data, the study found that “medical marijuana law adoption was associated with a 6% decrease in the odds of current marijuana use and a 7% decrease in the odds of frequent marijuana use.”

When it comes to recreational use, the news study found that prior to legalization, there was no association with marijuana use in the states analyzed. After 2 or more years, recreational marijuana law adoption was associated with a decrease in marijuana use.

Hot Medical Stocks To Own For 2022: Celldex Therapeutics Inc(CLDX)

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. The company markets Rotarix to treat rotavirus infection. Its lead drug candidate, rindopepimut (CDX-110), is an immunotherapeutic vaccine in Phase III clinical trial to target the tumor-specific molecule, epidermal growth factor receptor variant III, as well as in Phase II clinical trial for the indication of recurrent glioblastoma. The company?s other lead drug candidates comprise CDX-011, an antibody-drug conjugate in Phase IIb clinical trial for metastatic breast cancer and melanoma indication; and CDX-1127, a human monoclonal antibody in Phase I clinical trial for the treatment of lymphoma/leukemia and solid tumors. Its additional clinical and preclinical programs consist of CDX-1401, an Antigen Presenting Cells Targeting Technology program in Phase I/II clinical trial to tr eat multiple solid tumors; and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor in Phase I clinical for treating cancer, autoimmune disease, and transplant. The company?s preclinical products include CDX-1135, a molecule for treating renal disease; and CDX-014, a human monoclonal antibody-drug conjugate for the treatment of ovarian and renal cancer. It has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; Alteris Therapeutics, Inc.; Thomas Jefferson University; 3M Company; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. Celldex Therapeutics, Inc. was founded in 1983 and is headquartered in Needham, Massachusetts.

Advisors’ Opinion:

  • [By Keith Speights]

    Celldex Therapeutics (NASDAQ:CLDX) is in a much different place than it was one year ago. The biotech continues to feel the repercussions from the failure of glembatumumab vedotin (glemba) in the Metric clinical study targeting the treatment of triple-negative breast cancer.

  • [By Motley Fool Transcription]

    Celldex Therapeutics, Inc. (NASDAQ:CLDX)Q4 2018 Earnings Conference CallMarch 7, 2019, 4:30 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Hot Medical Stocks To Own For 2022: TripAdvisor, Inc.(TRIP)

TripAdvisor, Inc. owns and operates a portfolio of leading online travel brands. TripAdvisor, our flagship brand, is the world’s largest travel site. Our mission is to help people around the world plan and book the perfect trip. We accomplish this by, among other things, aggregating millions of travelers’ reviews and opinions about destinations, accommodations, activities and attractions, and restaurants throughout the world so that our users have access to trusted advice wherever their trips take them. Our platform not only helps users plan their trips with our unique user-generated content, but also enables users to compare real-time pricing and availability so that they can book hotels, vacation rentals, flights, activities and attractions, and restaurants.   Advisors’ Opinion:

  • [By Ethan Ryder]

    Fiera Capital Corp lowered its position in Tripadvisor Inc (NASDAQ:TRIP) by 2.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 714,552 shares of the travel company’s stock after selling 19,634 shares during the period. Fiera Capital Corp’s holdings in Tripadvisor were worth $38,543,000 at the end of the most recent quarter.

  • [By Jon C. Ogg]

    TripAdvisor Inc. (NASDAQ: TRIP) was downgraded to Underperform from Market Perform with a $40 price target (versus a $52.32 close) at Cowen.

    VMware Inc. (NYSE: VMW) was downgraded to Sell from Neutral with a $177 price target (versus a $172.69 close) at Goldman Sachs. VMware was among several tech leaders that have seen many upgrades prior to this call, and the consensus target price was $192.25. The 52-week trading range is $117.61 to $183.41.

Hot Medical Stocks To Own For 2022: MB Financial Inc.(MBFI)

MB Financial, Inc. operates as a bank holding company for MB Financial Bank, N.A. that provides various financial services to small and middle market businesses, and individuals in the United States. It offers commercial banking products and services, including credit products, comprising working capital loans and lines of credit, accounts receivable financing, inventory and equipment financing, industrial revenue bond financing, business acquisition loans, and owner occupied real estate loans, as well as financial, performance, and commercial letters of credit. The company?s commercial banking products and services also consists deposit treasury management products, such as Internet banking products, investment sweep accounts, zero balance accounts, automated tax payments, ATM access, telephone banking, lockbox, automated clearing house transactions, account reconciliation, controlled disbursement, detail and general information reporting, wire transfers, vault services for currency and coin, international banking services, capital markets products, and checking accounts, as well as provides various credit, deposit, and treasury management services for real estate operators and investors. In addition, it offers retail banking products and services; and wealth management solutions, which include banking, investment management, custody, personal trust, financial planning, wealth advisory services, estate settlement, guardianship, tax deferred exchange services, and retirement plan services. The company provides its services through operating 87 banking offices in Chicago, Illinois metropolitan area; and 1 banking office in Philadelphia, Pennsylvania. MB Financial, Inc. was founded in 1911 and is headquartered in Chicago, Illinois.

Advisors’ Opinion:

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on MB Financial (MBFI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on MB Financial (MBFI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    JPMorgan Chase & Co. (NYSE:JPM) and MB Financial (NASDAQ:MBFI) are both finance companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Hot Medical Stocks To Own For 2022: Navigant Consulting, Inc.(NCI)

Navigant Consulting, Inc. provides professional services to companies, legal counsel, and governmental agencies Worldwide. The company operates through four segments: Disputes, Investigations & Economics; Financial, Risk & Compliance; Healthcare; and Energy. The Disputes, Investigations & Economics segment provides accounting, financial and economic analysis, discovery support, and data management and analytics services on a range of legal and business issues, such as disputes, investigations, and regulatory matters. This segment serves in-house counsel and law firms, as well as accounting firms, corporate boards, and government agencies. The Financial, Risk & Compliance segment provides strategic, operational, valuation, risk management, investigative, and compliance consulting to the regulated financial services industry. This segment also provides anti-corruption solutions and anti-money laundering, valuation and restructuring consulting, and litigation support and tax compliance services to various industries. The Healthcare segment provides strategic, operational, performance improvement, and business process management services, which include solutions to clients across the healthcare landscape, including revenue cycle management, health systems, physician practice groups, health insurance providers, government, and life sciences companies. The Energy segment provides management advisory services on the issues, such as asset investment management, integrated resource planning, renewables, distributed generation, energy efficiency, and outage management and restoration. This segment serves utility, government, and commercial clients. Navigant Consulting, Inc. was founded in 1983 and is headquartered in Chicago, Illinois.

Advisors’ Opinion:

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Navigant Consulting (NCI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Navigant Consulting (NCI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Navigant Consulting (NYSE:NCI)’s stock had its “hold” rating reiterated by equities research analysts at William Blair in a research report issued to clients and investors on Sunday.

Hot Medical Stocks To Own For 2022: Vir Biotechnology, Inc.(VIR)

Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.

Advisors’ Opinion:

Hot Medical Stocks To Own For 2022: Vuzix Corporation(VUZI)

We are engaged in the design, manufacture, marketing and sale of wearable display and smart glasses devices known commercially as Video Eyewear (also referred to as head mounted displays (or HMDs), Smart Glasses, wearable displays, video glasses, personal viewers, near-eye virtual displays, and near-eye displays or NEDs). These devices are worn like eyeglasses and feature built-in video screens and in some cases a computer, that enable the user to view and interact with video and digital content, such as movies, computer data, the Internet or video games. Our Video Eyewear products provide virtual large high-resolution screens, fit in a user’s pocket or purse and can be viewed practically anywhere, anytime. They can also be used for virtual and augmented reality applications, in which the wearer is either immersed in a computer generated world or has their real world view augmented with computer generated information or graphics as is typical in enterprise applications.   Advisors’ Opinion:

  • [By Stephan Byrd]

    These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:

    Get Vuzix alerts:

    VUZI LOSS NOTICE: Rosen Law Firm Reminds Vuzix Corporation Investors of Important Deadline In Class Action – VUZI (finance.yahoo.com) SHAREHOLDER ALERT:Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Vuzix Corporation of Class Action Lawsuit and Upcoming Deadline VUZI (finance.yahoo.com) Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Vuzix Corporation (VUZI) (businesswire.com) Vuzix Corp (VUZI) Given Consensus Recommendation of “Hold” by Brokerages (americanbankingnews.com) Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against MEDNAX, Farmland Partners, and Vuzix and Encourages Investors to Contact the Firm (feeds.benzinga.com)

    Several brokerages have recently commented on VUZI. ValuEngine raised shares of Vuzix from a “hold” rating to a “buy” rating in a research note on Thursday, June 7th. Zacks Investment Research downgraded shares of Vuzix from a “hold” rating to a “sell” rating in a research note on Thursday, August 16th. Finally, Chardan Capital set a $10.00 price objective on shares of Vuzix and gave the company a “buy” rating in a research note on Friday, August 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $9.08.